- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 2023KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 553KB)
Ravulizumab – July 2020
Ravulizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Ultomiris®
Last updated
13 November 2020